The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study
- PMID: 20531207
- DOI: 10.1097/YIC.0b013e328338b884
The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study
Abstract
Catechol-O-methyltransferase (COMT) has been suggested to be involved in the pathogenesis and pharmacological treatment of affective disorders. The nonsynonymous single nucleotide polymorphism (SNP) in exon 4 (Val108/158Met; rs4680) influences the COMT enzyme activity. Inconsistent results were found between Val158Met polymorphism (rs4680) and treatment response phenotypes in genetic association studies. However, the haplotype combinations of alleles at the Val108/158Met SNP with the other synonymous SNPs in the COMT gene region have shown association between enzyme activity/amount and COMT-dependent phenotypes. We carried out this study to define the functional impact of COMT genotypes/haplotypes on susceptibility and on treatment response phenotypes of major depressive disorder (MDD). Three hundred and ninety-six patients with MDD diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [(DSM)-IV] and 295 healthy controls were recruited for this study and genotyped for the seven COMT SNPs (rs2075507, rs737865, rs6269, rs4633, rs4818, rs4680, and rs165599). This is the first study with all these SNPs to investigate for MDD and treatment response phenotypes. Our results show that none of the seven SNPs, including the rs4680, was significantly associated with MDD after permutation correction in single SNP analyses. Although several haplotype combinations showed significance, the combinations of G-T-G-G haplotype for rs6269, rs4633, rs4818 and rs4680 were only present in the MDD group (G-T 4.5%, corrected sim P=0.0001; G-T-G 3.87%, corrected sim P=0.001; G-T-G-G 3.3% corrected sim P=0.0025). In the treatment response phenotypes, the GG genotype of the rs2075507 SNP (located in the promoter region of MB-COMT) was less common in resistant patients in a single SNP analysis with low corrected sim P=0.052 and power=0.086. However, in the haplotype analysis, the haplotypes of exonic SNPs, rs4633, rs4818, and rs4680, were related to the treatment response phenotypes investigated, especially the phenotype of the response to antidepressant treatment. The C-C-A haplotype of these SNPs was overrepresented (almost four-and eight-fold) in the responders compared with the nonresponders and controls, respectively, after Bonferroni correction (corrected sim P=0.048, 0.0001, respectively). Both nonsynonymous and synonymous SNPs within haplotypes may be more relevant than the single SNP in conferring MDD susceptibility and treatment response phenotypes. Despite the limited power of our analysis, this finding suggests that the polymorphic COMT gene that influences catecholaminergic neurotransmission may play a role in the individual response to antidepressants.
Similar articles
-
The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder--a European multicenter study.Eur Neuropsychopharmacol. 2012 Apr;22(4):259-66. doi: 10.1016/j.euroneuro.2011.08.007. Epub 2011 Sep 21. Eur Neuropsychopharmacol. 2012. PMID: 21940152 Clinical Trial.
-
The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.Pharmacogenet Genomics. 2008 Sep;18(9):815-21. doi: 10.1097/FPC.0b013e328306c2f2. Pharmacogenet Genomics. 2008. PMID: 18698234 Clinical Trial.
-
Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.Pharmacogenomics J. 2007 Dec;7(6):418-26. doi: 10.1038/sj.tpj.6500441. Epub 2007 Mar 13. Pharmacogenomics J. 2007. PMID: 17363961 Clinical Trial.
-
Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD).CNS Neurol Disord Drug Targets. 2012 May;11(3):264-72. doi: 10.2174/187152712800672445. CNS Neurol Disord Drug Targets. 2012. PMID: 22483292 Review.
-
Association between COMT gene Val108/158Met and antidepressive treatment response: A meta-analysis.Gene. 2020 Apr 15;734:144333. doi: 10.1016/j.gene.2020.144333. Epub 2020 Jan 20. Gene. 2020. PMID: 31972309 Review.
Cited by
-
Interactions among catechol-O-methyltransferase genotype, parenting, and sex predict children's internalizing symptoms and inhibitory control: Evidence for differential susceptibility.Dev Psychopathol. 2015 Aug;27(3):709-23. doi: 10.1017/S0954579414000807. Epub 2014 Aug 27. Dev Psychopathol. 2015. PMID: 25159270 Free PMC article.
-
COMT Val(158)Met genotypes differentially influence subgenual cingulate functional connectivity in healthy females.Front Hum Neurosci. 2014 Jun 30;8:481. doi: 10.3389/fnhum.2014.00481. eCollection 2014. Front Hum Neurosci. 2014. PMID: 25071511 Free PMC article.
-
Polymorphisms of COMT and CREB1 are associated with treatment-resistant depression in a Chinese Han population.J Neural Transm (Vienna). 2022 Jan;129(1):85-93. doi: 10.1007/s00702-021-02415-y. Epub 2021 Nov 12. J Neural Transm (Vienna). 2022. PMID: 34767111
-
Genetic Landscape of Major Depressive Disorder: Assessment of Potential Diagnostic and Antidepressant Response Markers.Int J Neuropsychopharmacol. 2023 Oct 19;26(10):692-738. doi: 10.1093/ijnp/pyad001. Int J Neuropsychopharmacol. 2023. PMID: 36655406 Free PMC article.
-
No association between COMT val158met polymorphism and suicidal behavior: meta-analysis and new data.BMC Psychiatry. 2011 Sep 21;11:151. doi: 10.1186/1471-244X-11-151. BMC Psychiatry. 2011. PMID: 21936936 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous